Helixtalk - Rosalind Franklin University's College Of Pharmacy Podcast

In this episode, we discuss self-care of heartburn and dyspepsia, including antacids, bismuth subsalicylate, H2 blockers, and PPIs.

In this episode, we discuss the science of carbohydrate-based sugars, sugar alcohols, artificial sweeteners, and natural sweeteners with Dr. Eric Walters, author of the book "The Sweetener Book" and Professor at Rosalind Franklin University.

In this episode, we review the clinical presentation and treatment of diabetic ketoacidosis (DKA).

In this episode, we discuss the BRIDGE trial, which investigated whether patients with atrial fibrillation on warfarin need a parenteral anticoagulant "bridge" in preparation and after an elective surgical procedure.

In this episode, we discuss the 2015-2020 Dietary Guidelines for Americans published by the U.S. Department of Health and Human Services and U.S. Department of Agriculture.

In this episode, we discuss the many facets of homeopathic medications, including legal status in the United States, safety and efficacy data, and the ethics of homeopathy from the point of view of practicing pharmacists.

In this episode, we discuss nausea and vomiting of pregnancy (NVP) with a particular focus on Diclegis (doxylamine/pyridoxine).

In this episode, we discuss suvarexant (Belsomra), the first dual orexin receptor antagonist approved in the United States for the treatment of insomnia.

In this episode, we have an in-depth review of how to measure glomerular filtration rate (GFR), including variants of the Cockcroft-Gault equation and newer, more accurate methods that may eventually be used to renally adjust certain medications.

In this episode, we discuss two agents newly approved for schizophrenia -- Rexulti (brexpiprazole) and cariprazine (Vraylar).

In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.

In this podcast, we discuss three new injectable insulin formations: Toujeo (insulin glargine U-300), Humalog U-200 (insulin lispro), and Tresiba (insulin degludec).

In this episode, we discuss PCSK9 inhibitors, a new drug class for LDL lowering, with a particular focus on alirocumab (Praluent).

In this episode, we discuss the new drug class, ARNI, recently approved for heart failure with a focus on sacubatril/valsartan (Entresto) and the PARADIGM-HF trial.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for tacrolimus (Prograf) and lithium.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for valproic acid (Depakote/Depakene/Depakon) and digoxin (Lanoxin).

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for warfarin (Coumadin) and phenytoin (Dilantin).

In this episode, we discuss malaria prophylaxis with atovaquone/proguanil, chloroquine, hydroxychloroquine, doxycycline, mefloquine, and primaquine.

In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 2 of a 2 part episode.

In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years.  This is part 1 of a 2 part episode.